Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults

This study is testing whether rezafungin — an antifungal drug given by injection once a week — can effectively treat Pneumocystis pneumonia (PCP), a serious lung infection that commonly affects people with HIV whose immune systems are weakened. The study compares rezafungin to standard treatment to see if it is equally effective and safe. **You may be eligible if...** - You are 18 or older and HIV-positive - You have been diagnosed with Pneumocystis pneumonia (PCP) or are strongly suspected to have it - You are willing to use contraception during and after the study if applicable **You may NOT be eligible if...** - You are under 18 - You have a known allergy to any echinocandin antifungal drug (a family that includes rezafungin) or to co-trimoxazole (a standard PCP treatment) - You are pregnant or at risk of pregnancy without agreeing to contraception Talk to your doctor to see if this trial is right for you.